All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Clinical Laboratory and Imaging Correlates” took place.
One of the posters on display (3724 / 9) was titled “PDL1 protein expression and tumor mutation burden in hematologic malignancies: correlation with Hodgkin and high grade lymphoma” by Lina Abdul Karim, from MedStar Georgetown University Hospital, Washington DC, and colleagues.
Immunostaining using the FDA approved PD-L1 IHC 22C3 pharmDx assay was carried out on formalin fixed paraffin embedded sections from 92 hematological malignancies including Hodgkin Lymphoma (HL), Diffuse Large B-Cell Lymphoma (DLBCL), Low-Grade Non-Hodgkin Lymphoma (LGNHL), as well as Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Myeloma. Partial or complete membrane staining in all viable tumor cells was scored as follows: <1% negative, 1–49% low level, and >50% high level PD-L1 expression. Comprehensive Genomic Profiling (CGP) was also done in 2,064 cases.
The group concluded their poster by hypothesizing that the high PD-L1 expression in HL and DLBCL, and the high TMB in DLBCL, could potentially enhance responsiveness to check point inhibitor therapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox